Navigation Links
South Africa dilly-dallying on AIDS situation

South Africa, which is now the third most affected country by the AIDS virus, HIV, is in an unenviable position. One in every five South African is HIV positive. If this isn’t enough, the government is in the midst of a major controversy, as it refused a huge consignment of one million AIDS detecting kits free of cost estimated around seven million U.S. Dollars.

Earlier last year the South African president Thabo Mbeki caused a flutter when he openly questioned whether the HIV actually caused AIDS. He had then questioned the wisdom of the scientists and said the AIDS epidemic was overly played up.

Now the opposition has joined the worldwide condemnation of the South African government’s way of handling such an explosive situation.

However the government remains unruffled. On March 13th it refused to declare AIDS a national emergency. While South Africa can feel that the situation is not as bad as that in Botswana or Zimbabwe, health experts warn that unless the government pulls its socks up, the situation might soon go out of control.

'"/>




Page: 1

Related medicine news :

1. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
2. South Africa Wins landmark case against pharmaceutical giants
3. Over Six Million HIV Infected People In South Africa- Finds A Survey
4. The Kidney Transplantation conspiracy in South Africa
5. Phase II trails of new HIV vaccine to be held in South Africa
6. South Africa May Start Manufacturing Bird Flu Vaccines
7. Smoking Banned In Southeast Asian Games Venues
8. AIDS bias successfully overcome by Indian Muslims in South Africa
9. Increase in the Number of Cases of Animal Diseases in New South Wales.
10. Possibility Of Bird Flu Outbreak In South Africa Ruled Out
11. Mental Health Problems On The Rise In South Australia
Post Your Comments:
(Date:5/16/2008)... study being presented at the American Society of ...20), may change treatment practice in about 25 per...s for proposed changes to the way colorectal cance...ional Cancer Institute (NCI) SEER population-based... III clinical trial data, shows that outcomes of p...
(Date:5/16/2008)... fibroids located just beneath the lining of the u...endometrial cavity after uterine artery embolizati...s, according to a new study. , The study includ...MRI examination before and after UAE. The study fo...% migrated to the endometrial cavity after UAE, sa...
(Date:5/16/2008)...Live Web Cast Scheduled for May 19 at 10:15 a.m. E...all/ - Response Biomedical,Corporation (TSX: RBM, ...hief Executive Officer, is scheduled to present at... Conference on Monday May 19th at 10:15 a.m.,EDT.,...lable on the Company,s,Web site at, http://www.res...
(Date:5/16/2008)...elp docs determine who would benefit most from che... May 16 (HealthDay News) -- A panel of 15 genes ma...on-small cell lung cancer will experience a recurr...erapy, a new study shows. , By extension, the ...with less aggressive forms of the cancer who would...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3
...blished online in the Environmental Science & Tech...ty, says that bacteria present in the soil can con... the US to toxic forms that could prove harmful to... of environmental engineers at the University of C...
...ed this week says the government’s program (1999) ...ancially deprived families// and their children be...ers. The program targets individual families with...ved areas. It provides outreach or home visiting, ...
...nd or a relative learns that she has cancer she is...ough this, than about herself//. Questions as to h...keep life normal for them during her treatment oft... help, suggests Raising an Emotionally Healthy Chi...
...a's health minister, Manto Tshabalala-Msimang, cla...ne’s diet would delay the onset of AIDS//. She d... warned about the ill effects of the anti-retrovir...arked outrage among the AIDS activist and the medi...
Other Medicine News:Health News:Bacteria Can Convert Flame Retardant Into Toxic Form 2Health News:Helping a Family Going Through an Illness 2
(Date:5/15/2008)... /- Patients with breast or,colorecta...can expect,further treatment advances with Avastin...ollowing new data that is being presented at the 4...nnual meeting in Chicago at,the end of May. Around...ich,is the premier event for cancer therapy worldw...
(Date:5/15/2008)...SCO Showed Acceptable Tolerability Profile, ...hy, WOODCLIFF LAKE, N.J., May 15 /- ...n mesylate (E7389) demonstrated activity in a,heav...vanced or metastatic,breast cancer, according to r...The study also suggests that eribulin mesylate has...
(Date:5/15/2008)...nstrated in Blacks, Hispanics/Latinos, People ... PARSIPPANY, N.J., May 15 /- Daiichi ...at the American Society of,Hypertension,s Twenty- ...Orleans demonstrated that the powerful combination...l) safely and effectively helped,patients across s...
(Date:5/15/2008)...y 15 /- Ergonex Pharma today,announce...ion (FDA) has,granted orphan drug designation to T...ypertension (PAH). Terguride is currently being ev...ope., "The FDA,s grant of orphan drug designation...ur development program by offering regulatory,cli...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 2109 1HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 2109 2Industry Executives Finding Value in Shift of Scientific Publications 862 1Industry Executives Finding Value in Shift of Scientific Publications 862 2DuPont and Plantic Technologies Announce Starch Based Bio Materials Collaboration 860 1DuPont and Plantic Technologies Announce Starch Based Bio Materials Collaboration 860 2DuPont and Plantic Technologies Announce Starch Based Bio Materials Collaboration 860 3Mylan to Host Investor Day on October 3 2007 858 1
...rofile Reduction of,testosterone concentration was...r Shionogi initiates Phase 2b trial, QUEBEC CITY, ...ntaris Inc. along with its Japanese partner Shiono...s for a Phase 2a trial with,cetrorelix in benign p...pan. Results showed that cetrorelix, the Company,s...
...- Nutra Pharma,Corp. (OTCBB: NPHC), a biotechnolog...tiple Sclerosis has today announced that its,drug ...ification of,acceptance of its paper for publicati...onference issue., The article, entitled "Alpha-Cob...is; a review of the literature leading to its,deve...
Other Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
Features soft, low friction sheath that extends beyond the tip.
Facilitates intubation of tracheal tubes.
Disposable Aluminum Satin Finish E/T Stylette, Pediatric 11 1/2, 25/box.
Solid Copper Malleable with Adjustable Stop 14.75.
Medicine Products: